Copenhagen, Denmark, 22 April 2022 – Novo Growth, the growth-stage investment arm of Novo Holdings, today publishes its annual newsletter. Commenting on a highly successful year, Robert Ghenchev, Managing Partner, Head of Novo Growth, said: “Novo Growth’s unique platform combines deep life sciences expertise with long-term capital to make significant growth equity investments in companies across the life […]
Innovation award recognises STIMULAN Rapid Cure as the only calcium sulfate antibiotic carrier approved for use in bone and soft tissue International Trade award recognises Biocomposites’ outstanding continuous growth in overseas sales Keele, UK, 21 April 2022 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection […]
To meet the growing global demand for respiratory active pharmaceutical ingredients (APIs), Inke is to invest €9 million into its production plant to reinforce focus on inhalation micronised APIs Barcelona, Spain, April 20, 2022 – Inke, a leading global manufacturer of inhalation APIs wholly owned by Neuraxpharm Group, announces it is investing €9 million to increase […]
AMPLIVANT® adjuvant technology has the potential to increase vaccine immune response 10 – 100 fold Modi-1 clinical trial to begin in patients with triple negative breast cancer, ovarian cancer, head and neck cancer, and renal cancer Oegstgeest, The Netherlands, 14 April 2022 – ISA Pharmaceuticals today announces that a clinical trial using ISA’s novel AMPLIVANT® adjuvant […]
Brighton, United Kingdom – 12 April 2022 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces its audited financial results for the year ended 31 December 2021. Read more…
